Antitryptic property of cancer-related glycoprotein EDC1.
Cancer-related urinary glycoprotein EDC1 inhibits the action of trypsin and chymotrypsin on casein and synthetic substrates. The amino acid and carbohydrate compositions of EDC1 are different from those reported for pregnancy-related urinary trypsin inhibitors.
D002268:Carboxypeptidases / Q000037:antagonists & inhibitors; D002364:Caseins; D002918:Chymotrypsin; D005341:Fibrinolysin / Q000037:antagonists & inhibitors; D006023:Glycoproteins / Q000652:urine*; D006801:Humans; D007931:Leucyl Aminopeptidase / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000652:urine*; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors; D010434:Pepsin A / Q000037:antagonists & inhibitors; D011485:Protein Binding; D014105:Tosyl Compounds; D014361:Trypsin Inhibitors / Q000652:urine*; D014443:Tyrosine
D002364:Caseins; D006023:Glycoproteins; D014105:Tosyl Compounds; D014361:Trypsin Inhibitors; D014443:Tyrosine; D002268:Carboxypeptidases; D007931:Leucyl Aminopeptidase; D002918:Chymotrypsin; D010196:Pancreatic Elastase; D005341:Fibrinolysin; D010434:Pepsin A